By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Polaris 

1000 Winter Street
Suite 3350
Waltham  Massachusetts  02451  U.S.A.
Phone: 781-290-0770 Fax: 781-290-0880


SEARCH JOBS


Industry
Services

Segment
Investments





Company News
Biotech-Focused VC Firm Polaris Targets $400 Million For 7th Fund 6/26/2014 4:06:57 PM
Shaw T. Chen, M.D., Ph.D. Joins Polaris 4/3/2014 8:27:34 AM
Polaris Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma 10/28/2013 7:31:13 AM
Polaris of San Diego to Build $50 Million Facility in Chengdu 3/1/2013 11:16:18 AM
Polaris, Johnson & Johnson (JNJ) Hatch Idea to Solve Drug R&D Crisis: Work Together Early 6/14/2012 8:19:36 AM
Polaris is the Winner of the 2011 Pierre Potier Price Trophy for its Innovation in Chemistry in Favour of Sustainable Development 7/12/2011 9:45:07 AM
Ludwig Institute For Cancer Research (LICR) and Polaris Form Collaboration to Expand Development of Polaris' Novel Cancer Drug, ADI-PEG 20 5/18/2011 9:15:10 AM
Polaris to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 5/12/2011 7:06:14 AM
Polaris Release: Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy 4/11/2011 8:50:27 AM
Polaris Release: Transcriptional Silencing of ASS1 Suggests the Potential Use of ADI-PEG 20 to Treat AML, Glioblastoma and Bladder Cancer 4/8/2011 7:04:12 AM
12
//-->